Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01890213 · ClinicalTrials.gov registry record · Phase 1
Immunotherapy With CEA(6D) VRP Vaccine (AVX701) in Patients With Stage III Colorectal Cancer
A Phase 1 study, sponsored by Duke University.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT01890213 is a Phase 1 study that has completed, run by Duke University. The registered enrollment target is 12 participants.
The verdict
NCT01890213, a Phase 1 study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
This is a pilot study to evaluate the safety of a vaccine that consists of an alphavirus replicon (VRP) encoding the protein (CEA) that has been found to be associated with cancers such as colon cancer in patients that have stage III colon cancer. We will also evaluate the patient immune response to the vaccine.
Interventions
- BIOLOGICAL AVX701
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2013-11 |
| Est. Completion | 2019-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01890213
The ClinicalTrials.gov registry entry for NCT01890213 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AVX701 is the first listed.
NCT01890213 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01890213 about?
NCT01890213 is a clinical study titled "Immunotherapy With CEA(6D) VRP Vaccine (AVX701) in Patients With Stage III Colorectal Cancer". This is a pilot study to evaluate the safety of a vaccine that consists of an alphavirus replicon (VRP) encoding the protein (CEA) that has been found to be associated with cancers such as colon cancer in patients that have stage III colon cancer. We will also evaluate the patient immune response to...
What is the current status of trial NCT01890213?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2013-11. Estimated completion is 2019-07.
What interventions are being tested in trial NCT01890213?
The interventions under investigation include: AVX701 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01890213?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.